Genmab in the Netherlands has doubled the number of licenses it owns for ActivityBase XE, which it uses to capture and store plate-based screening data.
The biotech company needed a flexible solution to handle the data produced from the functional screening of human monoclonal antibody therapies, used in the treatment of cancer and infectious diseases.
ActivityBase XE enables the scientists to capture, validate and visualise the data from antibody screening in a contextually rich environment.
Arnout Gerritsen, senior manager of lead identification at Genmab, commented: ‘The introduction of ActivityBase XE into our Hybridoma Discovery department has significantly improved the efficiency of our human antibody screening campaigns. The flexibility inherent within the ActivityBase XE module enables us to use both Excel and non-Excel templates in our analysis.’